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ABSTRACT 
 
 
Introduction: Intrahepatic cholestasis of pregnancy (ICP) is a reversible liver disorder 
occurring during pregnancy. It has a typical genetic background with known genetic 
mutations and can be considered as an expression of this genetic predisposition. The 
objective of this study was to determine whether ICP is associated with specific long-term co- 
morbidity. Material and methods: The study population comprised 571 women with ICP in 
at least one pregnancy who were compared with 1333 pregnant women without ICP during 
the years 1969-1988 at Tampere University Hospital, Finland. The cohort's follow-up time 
was 44 years. All ICD-10 classification discharge diagnoses were examined for the women in 
the ICP group from 1998 to 2013 and ICD-10 diagnoses from outpatient care from 1969 to 
2013. Results: At least one disease of the digestive system had been diagnosed in 50.4% 
(288/571) of the ICP mothers compared with 34.4% (459/1333) of the reference group 
(p<0.001). In a more detailed analysis women with a history ofICP had an increased risk for 
cholelithiasis and/or cholecystitis (odds ratio (OR) 2.88, 95% confidence interval (Cl) 2.17 to 
3.84), diseases of the pancreas (OR 2.26, 95% CI 1.20 to 4.27), and hypothyroidism (OR 
2.38, 95% CI 1.27 to 4.46) compared with the reference group. Arterial diseases were less 
common in the ICP mothers compared to the reference group (OR 0.38, 95% CI 0.15 to 
0.99). Regarding other diseases, there were no statistically significant differences between the 
ICP mothers and reference group. Conclusions: Half of the women with a history ofICP 
have been diagnosed with at least one disease of the digestive system compared with a third 
in the reference group. The risk of cholelithiasis, cholecystitis, diseases of the pancreas and 
hypothyroidism is increased compared with the reference group. These are important facts 
when counselling women after a pregnancy with ICP. Also, this is of importance for the 
general practitioners and other physicians who take care of these women. 
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Key Message: 
The study investigates the cohort's long-term co-morbidity over a 44-year follow-up. 
Hypothyroidism and diseases of the digestive system were found to be associated with 
cholestasis of pregnancy. The cohort and the controls had no other significant differences in 
co-morbidity. 
 
INTRODUCTION 
 
 
Intrahepatic cholestasis of pregnancy (ICP) is a liver disorder during pregnancy. The 
incidence of ICP varies geographically from 0.2% to 2%, being the most common in South 
America and northern Europe (1). It typically manifests at the late second or third trimester of 
the pregnancy. The diagnosis requires itching as a symptom and elevated liver enzymes 
and/or increased bile acids when measured in maternal serum. The diagnosis ofICP is by 
exclusion, when no other explanation is found for maternal symptoms and the elevated liver 
enzymes and/or bile acids. ICP mothers' deliveries are more likely to be complicated, with 
preterm delivery, fetal distress, and intrauterine fetal death (1). The biochemical 
abnormalities and itching resolve quickly after delivery (2). 
 
 
Non-alcoholic cirrhosis with liver fibrosis, hepatitis C and nonspecific hepatitis are more 
common in ICP mothers than they are in controls from the Finnish population. The same is 
true for cholelithiasis and cholecystitis, biliary system disorders and non-alcoholic 
pancreatitis (3). In the study by Ropponen and colleagues the follow-up time started from the 
first ICP pregnancy. It has been observed that ICP is associated with later diabetes, psoriasis, 
inflammatory polyarthropathies and thyroid disease (4). An association between ICP and self- 
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repmied hypothyroidism and hepatobiliary diseases has been found (5). Self-reported breast 
cancer was higher in women with ICP compared to controls (5) but this association was not 
found in a registry-based study (6). In our study, the cohort was the same as reported in the 
studies by Turunen (2012) and Hamalainen (2017) (5,6). 
 
ICP is associated with an increased risk for preeclampsia and gestational diabetes (7), both of 
which are risk factors for cardiovascular disease later in life (8,9). In a questionnaire study, 
women with a history ofICP reported less cardiac arrhythmia than the reference group, as 
well as high cholesterol and high blood pressure requiring medication (5). 
Genetic predisposition, immune response, gestational hormones, and environmental factors 
are suggested to influence ICP's pathogenesis (2). The hepatic phospholipid transporter 
(MDR3/ABCB4), the aminophospholipid transpmier (ATP8Bl/FIC1), and the bile salt 
export pump (BSEP/ABCB11) have been found to include mutations in patients with ICP (2). 
 
The development ofICP can be considered an expression of this genetic predisposition but 
what triggers the disease, other than pregnancy itself, is unknown. The aim of this study is to 
investigate whether ICP is associated with a specific co-morbidity later in life, by tracking 
ICD-10 diagnostic codes from medical records from hospitals and out-patient clinics. 
 
MATERIAL AND METHODS 
 
 
The cohort comprised all ICP pregnancies from the medical records of Tampere University 
Hospital (TUH) during the years 1969-1988. Diagnosis codes were used to identify patients 
with ICP in the hospital discharge registry. ICD-8 disease classification system was used at 
TUH from 1969 to 1986, and because ICD-8 did not include a precise code for ICP, we 
checked all the obstetric codes that might contain ICP: 637.9 Toxicosis NUD, 639.00 
Pruritus, 639.01 Icterus gravis, 639.09 Necrosis acuta et subacuta hepatis, and 639.98 Aliae 
definitae. Thereafter, we checked the handwritten diagnosis behind the code, and if it referred 
to ICP, we included the case for further selection. ICD-9 disease classification system was 
used at TUH between 1987 and 1988, and it contained the appropriate codes: 6467A 
Hepatosis gravidarum and 6467X Hepatopathia alia. ICD-10 disease classification system has 
been used from the year 1996. The diagnosis was verified in each patient record by the 
presence of the main symptom of itching and abnormal laboratory test results. At least one of 
the following was required: ASAT >35 U/1, ALAT >40 U/1, or bile acids 2':6 µmol/1(10). 
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The study population comprised 687 ICP deliveries and 1374 women without ICP which 
served as a control group. The data included some women with separated ICP deliveries 
during the years 1969-1988, and each of these women was studied as an individual case, 
hence the rep·group contained a total of 575 women. None of the controls was twice as a 
control and none of the women was in both groups. The previous  and  following  subjects  in 
the maternity ward diary were taken  as controls  for each  ICP case, so initially  there were 
twice as many controls as ICP women. None of the controls had been diagnosed with ICP. 
There were no other exclusion criterions. In a questionnaire study with the same cohort the 
groups were comparable in terms of age, educational level, and body mass index (5). The 
groups did not differ regarding mean age at the time of delivery (28.0 years in the ICP group 
and 27.6 in the reference group). Four women from the ICP cases and 41 from the references 
were ruled out because of missing personal identity codes. The final cohort comprised 571 
women with ICP and 1333 controls. The  analyses  were  made comparing  these two groups, 
not in a case-control manner. 
 
The diagnoses were gathered from the Finnish Hospital Discharge Register. Everyone in 
Finland who has been admitted to specialized inpatient care, undergone outpatient surgery, or 
visited specialized outpatient care is included in the statistics (11). The data contain all the 
cohort's hospital discharge diagnoses from 1969 to 2013, including diagnoses made in 
specialized outpatient care from 1998 to 2013. The data from the Finnish Hospital Discharge 
Register included the diagnosis according to ICD-8 during the years 1969-1986 and ICD-9 
during the years 1987-1995. ICD-10 classification system has been used from the year 1996 
(12). 
 
Statistical Analyses 
The data were analysed using the SPSS for Windows, Version 23.0. The results are presented 
as frequencies and percentages. Statistical significance was tested with the chi-squared test, 
and p-values <0.05 are considered statistically significant. Binary logistic regression was 
used to achieve odds ratios (OR) and 95% confidence intervals (CI), with the dependent 
variable being 'ICP or not'. 
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Ethical approval 
The study was approved by the Regional Ethics Committee of Tampere University Hospital 
(R02149) and the National Institute for Health and Welfare, Finland 
(THL/1051/5.05.00/2014). 
 
RESULTS 
 
 
Diseases of the digestive system (K00-K99, ICP not included) were diagnosed in half of the 
ICP mothers (50.4%) and in a third of the control group (34.4%) (p<0.001). For the 
occurrence of other diagnoses as classified by the ICD-10 classification groups, there was not 
a statistically significant difference between ICP women and controls. Common diagnoses for 
both ICP mothers and the control group were from the genitourinary system (51.0% and 
51.5%), the musculoskeletal system (47.6% and 43.6%) and the cardiovascular system 
(44.0% vs 40.7%). Neoplasia had occurred in 41.5% of the ICP mothers and 36.9% of the 
women in the control group. (Table 1) 
 
When taking a closer look at individual diagnoses from the ICD- IO classification groups a 
statistically significant difference was found in the occurrence of thyroid (7.0% vs 4.6%; 
p=0.03) disorders among ICP women and controls. Arterial diseases were more common in 
controls (0.9% vs 2.3%; p=0.04; OR 0.38, 95% CI 0.15 to 0.99). Regarding occurrence of 
other disease groups there were no differences. (Table 2). 
 
 
The occurrence of different thyroid diseases in the ICP mothers and references are presented 
in Table 3. Hypothyroidism was diagnosed in 3.5% (n=20) of the ICP mothers and in 1.5% 
(n=20) of the references (OR 2.38, 95% CI 1.27 to 4.46). Five of the ICP mothers and none 
of the control group had two different diagnoses among the disorders of thyroid gland: of the 
ICP mothers, three had been diagnosed with hypothyroidism and thyrotoxicosis and two with 
hypothyroidism and goiter. 
 
Hepatobiliary diseases (ICP not included)  were diagnosed  in 35.2% (n=201)  of the ICP 
mothers and in 11.6% (n=155) of the references (p<0.001). Diseases of the digestive system 
other than hepatobiliary diseases were diagnosed in 28.4% (n=162) of the ICP mothers and in 
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27.5% (n=366) of the reference group (p=0.68). Table 4 shows that cholelithiasis and/or 
cholecystitis (OR 2.88, 95% CI 2.17 to 3.84) and diseases of the pancreas (OR 2.26, 95% CI 
1.20 to 4.27) were found significantly more often in the ICP mothers than in the reference 
group. Five hepatitis cases were diagnosed in the cohort up to 2013, and two of them being 
hepatitis C. 
 
DISCUSSION 
 
 
Hepatobiliary diseases were overrepresented in women with a history ofICP. Moreover, 
there was a higher occurrence of thyroid gland diseases in the mothers with ICP, especially 
goiter and hypothyroidism. In contrast, the occurrence of arterial diseases was lower in the 
ICP group. Cholelithiasis and/or cholecystitis and diseases of the pancreas were more 
common in the ICP mothers than in the reference group. Regarding other disease groups, 
there were no statistically significant differences between the ICP mothers and controls. 
Genitourinary, musculoskeletal and cardiovascular diseases were the most common diseases 
among both groups. 
 
The strength of our study is the extensive cohort including all  ICP cases diagnosed  at TUH 
from 1969 to 1988. Another strength of the study is the long follow-up time of 44 years. In 
addition, our data include all diagnoses made in specialized health care. The Finnish Hospital 
Discharge Register is one of the oldest national hospital discharge registers in the world. The 
completeness and accuracy of the register seem to vary from satisfactory  to very  good  (13). 
The data can thus be considered reliable and valid. 
 
The weakness of our study is that the data do not contain diagnoses made in primary health 
care. Hypothyroidism, asthma, and high blood pressure, for example, are usually followed-up 
and treated in primary healthcare in Finland. We do not have records of parity for either the 
ICP group or the reference group. A few of the women may have had a delivery even before 
1969, when the follow-up started. Our aim in this study was to compare morbidity between 
women with ICP and the reference group, and we did not analyze the time from ICP to the 
diagnosis of a hypothyroid condition. In futiher studies, the period from ICP to the diagnosis 
of various diseases might be of great interest. The threshold values of laboratory tests for ICP 
diagnosis were lower in 1969-1988 than at present. Nevertheless, the ICP diagnosis was 
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made at TUH according to the custom of the time and the diagnosis can be regarded as 
adequate. The upper limit of normal bile acids can be reduced to between 6 and 10 µmol/1 in 
fasted women although many studies use an upper limit of normal between 10 and 14 µmol/1 
(2). In our study, the results can be considered  similar, even  though  the diagnostic  criterion 
for ICP was a bile acid concentration ?.6 µmol/1 instead of?.l O µmol/1. 
 
 
The diagnoses were extrapolated to ICD-10 as in a previous Swedish study (4). More 
accurate analyses were made with diagnosis codes that had not been used in previous ICP 
studies. If the code in ICD-8 or -9 was less accurate than in ICD-10, the diagnostic 
classification was made by the superior code heading. The possibility of misdiagnosis may be 
considered low. 
 
 
A population-based study observed a diagnosis of cardiovascular diseases more often in 
women with ICP than in the controls (4). In the aforementioned study, the occurrence of 
cardiovascular diseases in the ICP group was nearly 11%, which is lower than in our study. In 
a questionnaire study on the same cohort, cardiac arrhythmia, high cholesterol, and high 
blood pressure requiring medication were reported less frequently in the ICP group (5). 
Furthermore, in the present study there was a lower incidence of arterial diseases in the ICP 
group than in the reference group. The same population-based study did not find any 
difference regarding arterial diseases between women with ICP and their controls (4). The 
older age of our cohort might explain why the differences were found in the present study. 
 
The association between ICP and the increased risk for hepatobiliary diseases is well known 
(3,5,14). In our study, over half of the women with a history ofICP had been diagnosed with 
diseases of the digestive system, which is significantly  greater compared  to the diagnosis  rate 
in the reference women. The risk for cholecystitis and cholelithiasis in women with ICP was 
remarkably higher than it was in the references. The findings are in agreement with previous 
research. 
 
Diseases of the pancreas were more common  in the  ICP  group compared  to the reference 
group. Prior to this study, non-alcoholic pancreatitis was found to be more common in ICP 
patients than in controls (3). Our study found an increased  risk for cholecystitis  and 
cholelithiasis in the ICP mothers. Patients with pancreatitis may also have cholecystitis, and it 
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is plausible that only one of the diagnoses had been noted down in the medical records. 
However, the records of women with ICP presumably  have the same weakness  as the records 
of the references. 
 
Hypothyroidism was more commonly diagnosed in the women with ICP than in the reference 
group. It is commonly noted that autoimmune pathogenesis has a remarkable effect on 
hypothyroidism (15). It can be speculated that there might also be an autoimmune aspect in 
the pathogenesis ofICP. However, it should be noted that there might be overdiagnosis of 
hypothyroidism but this can be regarded similar in both groups (16). 
 
To cross-validate our results, we repeated the study using the patient records of our cohort 
members from the Finnish Cancer Registry. Slightly more of the ICP mothers were diagnosed 
with breast cancers compared to the controls. (6). However, such a difference between the 
groups was not found in the present study. The explanation for the difference between these 
two studies might be that the Cancer Registry data (6) had a longer follow-up time. 
 
ICP has been linked with various genetic mutations, and the genetic background has an effect 
on the pathogenesis of ICP (2). Although differences regarding the co-morbidity in the ICP 
and the reference groups were found, the explanation might be the genetic predisposition 
rather than the history of ICP itself. The shared risk factors, such as mutations in particular 
genes, might influence the pathogenesis ofICP and also other diseases of the digestive 
system. Both ICP and gallstone diseases are associated with the ABCB4 gene (17-19). 
 
CONCLUSION 
 
 
Half of the women with a history ofICP have been diagnosed with at least one disease of the 
digestive system compared with a third in the reference group. The risk of cholelithiasis, 
cholecystitis, diseases of the pancreas and hypothyroidism was increased compared with the 
reference group. These are imp01iant facts when counselling women after a pregnancy with 
ICP. Also, this is of impo1iance for the general practitioners and other physicians who take 
care of these women. 
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Table 1. The incidence(%) of specific ICD 10 disease groups in the intrahepatic cholestasis 
of pregnancy (ICP) women and the control group. 
 
 
 
ICD-lOcode ICP Controls Difference 
N=571 N=l333 
n % n % % units p-value 
 
Diseases of the digestive 
system (ICP not included) 
K00-K99 288 50.4 459 34.4 16.0  <0.001  
Neoplasms C00-D48 237 41.5 492 36.9 4.6  0.06 
Diseases of the 
musculoskeletal system and 
connective tissue 
M0O-M99 272 47.6 581 43.6  4.0 0.10  
Diseases of the 
cardiovascular system 
IO0-I99 251 44.0 542 40.7  3.3 0.18  
Endocrine, nutritional, and 
metabolic diseases 
E00-E90 103 18.0 215 16.1  1.9 0.31  
Diseases of the nervous 
system and sense organs 
G00-H95 232 40.6 526 39.5  1.1 0.63  
Symptoms, signs, and R00-R99 294 51.5 682 51.2 0.3  0.90  
abnormal clinical and 
laboratory findings not 
elsewhere classified 
         
Diseases of the genitourinary 
system 
N00-N99 291 51.0 687 51.5  -0.5 0.82  
Diseases of the blood and 
blood-forming organs and 
D50-D89 15 2.6 43 3.2  -0.6 0.49  
certain disorders involving 
the immune mechanism 
         
Diseases of the respiratory 
system 
JO0-J99 146 25.6 356 26.7  -1.1 0.61  
Infectious and parasitic 
diseases 
A00-B99 62 10.9 164 12.3  -1.4 0.37  
Mental and behavioral 
disorders 
F00-F99 89 15.6 228 17.1  -1.5 0.42  
Injury, poisoning, and certain S00-T98 203 35.6 497 37.3 -1.7 0.47 
other consequences of 
external causes 
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 Congenital malformations, 
deformations, and 
chromosomal abnormalities 
Q00-Q99 13 2.3 54 4.1 -1.8 0.05 
 Diseases of the skin and 
subcutaneous tissues 
L00-L99 80 14.0 221 16.6 -2.6 0.16 
 
* The results include all subjects who have at least one of these diagnoses. 
 
 
Table 2. The occurrence(%) of neoplasms, disorders of the thyroid gland, immune-mediated 
diseases, cardiovascular diseases, pregnancy-associated diseases, and in the intrahepatic 
cholestasis of pregnancy (ICP) mothers and the control group. 
 
 
ICD-10 code ICP Controls  Difference  
 N=571 N=l333   
 n % n % % units p- 
     value 
Neoplasms 
Breast cancer C50 
 
36 6.3 
 
66 
 
5.0 
 
1.3 
 
0.30 
Liver and biliary C22-C24 
tract cancer 
0 0.0 0 0.0 0.0  
Malignant diseases C00-D48 
other than the 
aforementioned 
216 37.8 458 34.4 3.4 0.15 
Diseases of the thyroid E00-E07 40 7.0 61 4.6 2.4 0.03 
gland       
Immune-mediated diseases 
Diabetes mellitus 
 
E10-E14 
 
34 6.0 
 
97 
 
7.3 
 
-1.3 
 
0.30 
Sarcoidosis D86 2 0.4 5 0.4 0.0 0.94 
Crohn's K50 3 0.5 5 0.4 0.1 0.64 
Ulcerative colitis K51 6 1.1 10 0.8 0.3 0.51 
Celiac disease K90.0 6 1.1 13 1.0 0.1 0.88 
Inflammatory M05-M09 20 3.5 46 3.5 0.0 0.96 
polyarthropathies       
Systemic connective M32 1 0.2 3 0.2 0.0 0.83 
tissue disorders       
Asthma 145 28 4.9 72 5.4 -0.5 0.66 
Psoriasis 140 8 1.4 27 2.0 -0.6 0.35 
Cardiovascular diseases       
Hype1iensive disease 110-115 67 11.7 178 13.4 -1.7 0.33 
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 Coronary heart 121-125 27 4.7 65 4.9 -0.2 0.89  
disease        
Pulmonary heart 
disease 
126 8 1.4 18 1.4 0.0 0.93 
 Cerebrovascular 
disease 
127-28 G4S 22 3.9 56 4.2 -0.3 0.73 
 Arterial diseases 170-179 5 0.9 30 2.3 -1.4 0.04 
Pregnancy-associated 
diseases 
  Preeclampsia 014.0-014.2 23 4.0 72 5.4 -1.4 0.21 
  Gestational diabetes 024.4 9 1.6 24 1.8 -0.2 0.73  
 
 
* The results include all subjects who have at least one of these diagnoses. 
 
 
 
Table 3. Risk (OR with 95% CI) for at least one disease of the thyroid gland in the 
intrahepatic cholestasis of pregnancy (ICP) mothers and the control group. 
 
 
 
 Disease of the thyroid gland ICD-10 code  n % OR 95%CI  
Thyroiditis E06 Controls 4 0.3    
  ICP 3 0.5 1.76 0.39---7.87  
Goiter E0l.0-E0l.2 E04 Controls 22 1.7    
  ICP 17 3.0 0.55 0.29---1.04  
Thyrotoxicosis E05 Controls 14 1.1    
  ICP 4 0.7 1.51 0.49---4.60  
Hypothyroidism E0I.8 E02-E03 Controls 20 1.5    
  ICP 20 3.5 2.38 1.27-4.46  
Other disorders of the thyroid gland E00-E07 (excluding the Controls 1 0.1    
  aforementioned)  
ICP 
 
0 
 
0.0 
 
- 
  
* Five of the ICP mothers and none of the controls had two different diagnoses among 
diseases of the thyroid gland. 
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Table 4. Risk (OR with 95% CI) for at least one mentioned hepatobiliary  disease or disease  
of the pancreas in the intrahepatic cholestasis of pregnancy (ICP) mothers and the control 
group. 
 
 Hepatobiliary disease ICD-10  n % OR 95%CI  
Cholecystitis and/or cholelithiasis K80-K81 Controls 106 8.0    
   
ICP 
 
114 
 
20.0 
 
2.88 
 
2.17-3.84 
 
 Diseases of the pancreas K85-K86 Controls 20 1.5    
   ICP 19 3.3 2.26 1.20-4.27  
 Cirrhosis of the liver K.70.2 K.76.1 K.70.3 
P78.8 K.71.7 K.74 
Controls 8 0.6    
   ICP 7 1.2 2.06 0.74-5.70  
 
